FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Fulcrum Therapeutics, Inc. (
NASDAQ: FULC) and Slate Medicines, Inc. Upon closing of the proposed transaction, Fulcrum shareholders are expected to own 5.0% of the combined company.
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine TherapiesCombined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Alerts Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Possible Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Notifies Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) of an Investigation Into Potential Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Announces an Investigation Into Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm to Learn About Their Legal RightsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox & Kilsheimer LLP Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to a Securities InvestigationSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPNEW YORK, NY - June 20, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (
NASDAQ: FULC).
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the FirmNEW YORK, NY - June 19, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (
NASDAQ: FULC).
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the FirmSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law ViolationsNEW YORK, NY - June 18, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (
NASDAQ: FULC).
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law ViolationsNEW YORK, NY - June 17, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (
NASDAQ: FULC).
FULCRUM THERAPEUTICS Investors are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law ViolationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
FULCRUM THERAPEUTICS Investors are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law ViolationsNEW YORK, NY - June 16, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (
NASDAQ: FULC).
Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)NEW YORK, NY - June 10, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (“Fulcrum Therapeutics” or the “Company”) (
NASDAQ: FULC).
